TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03830918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT06462859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy Group
Description: The experimental group received sensory integration therapy in addition to the NDT program. The NDT program is customized for each child, featuring a unique blend of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. Participants attended 45-minute NDT and sensory integration sessions three times a week for 8 weeks. Sensory integration therapy, visual perception activities (block design, shape recognition in pictures, puzzles, matching geometric shapes and letters, numbers and classification exercises), body awareness activities (showing body parts, drawing life-size drawings, turning left and right, recognizing body parts by touching ), tactile perception exercises (feeling and touching various textures and shapes) and visual-motor coordination training (eye tracking exercises, activities with moving objects and panel activities).

Intervention type: OTHER
Group type: OTHER
Intervention: Neurodevelopmental Treatment Group
Description: The NDT program is customized for each child, featuring a mix of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. He attended 45-minute NDT sessions three times a week for 8 weeks. There is no treatment or medication other than NDT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Treatment Group
Description: The NDT program is customized for each child, featuring a mix of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. He attended 45-minute NDT sessions three times a week for 8 weeks. There is no treatment or medication other than NDT.
Study: NCT04018586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVACEN 100
Description: AVACEN 100 pulls a -30mmHg vacuum around hand from wrist down and applies heat (108 farenheit) to the palm and will be applied for 30 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AVACEN 100 Heat Only
Description: AVACEN 100 applies heat (108 Fahrenheit) to the palm and will be applied for 30 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AVACEN Sham
Description: AVACEN 100 neither heats nor pulls a vacuum to hand
Study: NCT03290170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measured Resection
Description: Bony landmarks are used to set femoral component rotation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gap Balancing
Description: Relies on ligament releases prior to bone cuts.
Study: NCT01578538

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inguinal hernia repair
Description: strangulated hernias will be repaired surgically

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inguinal hernia repair
Description: strangulated hernias will be repaired surgically
Study: NCT01229514

Intervention type: OTHER
Intervention: fMRI
Description: fMRI and a response inhibition task to examine activation patterns in the prefrontal cortex and caudate nucleus

Intervention type: OTHER
Intervention: fMRI
Description: fMRI and a response inhibition task to examine activation patterns in the prefrontal cortex and caudate nucleus
Study: NCT04344262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium Besylate regular dose
Description: Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atracurium Besylate minial dose
Description: atracurium boluses of muscle relaxant given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal
Study: NCT02099487

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: hypofractionated IMRT
Study: NCT00907972

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03514004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICT-based intervention
Description: The ICT-based intervention, known as Project Clan, includes both a web-platform and a mobile application. Project Clan includes both informational and interactive features, ranging from traditional suicide prevention strategies (e.g., a chat with a psychologist, emergency phone hotline, and tips) that seek to reduce barriers to access quality, useful, and evidence-based information and rapid professional assistance, to components designed to increase interactions between participants and promote a sense of belonging and connection with the other Clan members.
Study: NCT00511849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin + SU011248 (sunitinib) + paclitaxel
Description: AUC of 6 mg\*min/mL administered as a 30-minute infusion, every 21 days for 4 cycles or until progression/unacceptable toxicity. 25 mg, 37.5 mg, or 50 mg (depending on the dose level assigned) orally taken every day or for 2 weeks and 1 week off without for 4 cycles or until progression/unacceptable toxicity. 175 mg/m2, 200 mg/m2, or 225 mg/m2 (depending on the dose level assigned), administered as a 3-hour infusion every 21 days for 4 cycles or until progression/unacceptable toxicity.
Study: NCT04048538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precare
Description: an innovative patient education platform using animated videos created by using up-to-date evidence-based informaiton

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual standard of care
Description: individuals will receive treatment as per the usual standard of care
Study: NCT00378976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir
Description: 500 mg twice-daily oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: twice daily as per experimental drug
Study: NCT03594864

Intervention type: PROCEDURE
Intervention: Liver transplantation with hyper-reduced grafts
Description: Live donor liver transplantation using non-anatomical in-situ ultrasound-guided reduction of left lateral segments with preparation of a graft that is larger than a monosegment, but smaller than Segments 2 and 3.
Study: NCT00444964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutropin AQ
Description: 0.0125 mg/kg/day
Study: NCT01142479

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese herbal medicine decoction
Description: 100 ml /Qd for 6 weeks(42 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine decoction
Description: 100 ml /Qd for 6 weeks(42 days)
Study: NCT01052181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Oral Cholecalciferol sachets 120,000 IU monthly for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 sachets monthly for an year
Study: NCT01455415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 150 - 300 mg/day in divided dose (3 time a day) for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo 3 time a day
Study: NCT00033228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MKC1106-MT
Description: Cancer Vaccine, Immunotherapy, 500 ug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MKC1106-MT
Description: Cancer Vaccine, Immunotherapy, 1000 ug
Study: NCT01411423

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients who have received Nexavar for unresectable or advanced RCC.
Study: NCT02994745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan, Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan, Atorvastatin
Study: NCT00033228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MKC1106-MT
Description: Cancer Vaccine, Immunotherapy, 1500 ug
Study: NCT02427100

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet/Physical Activity
Description: Diet/Physical Activity Intervention
Study: NCT03509844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Three established psychotherapeutic models for treatment of complex posttraumatic stress disorders are compared in a residential care setting. Combination of group and individual sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Three established psychotherapeutic models for treatment of complex posttraumatic stress disorders are compared in a residential care setting. Combination of group and individual sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Three established psychotherapeutic models for treatment of complex posttraumatic stress disorders are compared in a residential care setting. Combination of group and individual sessions.
Study: NCT00407550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine HCL
Description: 1250 mg/m\^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 \& 8 of each cycle (21 days) x6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: 500 mg/m\^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: 500 mg/m\^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine HCL
Description: 1500 mg/m\^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.
Study: NCT02796833

Intervention type: DRUG
Group type: OTHER
Intervention: SMOFlipid20%
Study: NCT04594629

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Nitroglycerin
Description: Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
Study: NCT03963037

Intervention type: OTHER
Intervention: Blood draw
Description: Draw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.

Intervention type: OTHER
Intervention: Blood draw
Description: Draw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.
Study: NCT04594629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGI2
Description: Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres
Study: NCT06109519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported overdenture
Description: patients would be delivered mandibular implant overdenture using conventional locator and Locator RTX attachments

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported overdenture
Description: patients would be delivered mandibular implant overdenture using conventional locator and Locator RTX attachments
Study: NCT00917566

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: intubation with airtraq

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintoch
Description: use Macintoch laryngoscope for intubation
Study: NCT02544399

Intervention type: OTHER
Intervention: 3D CT scan
Description: Measure of bone micro-architecture by 3D micro-tomography

Intervention type: OTHER
Intervention: 3D CT scan
Description: Measure of bone micro-architecture by 3D micro-tomography

Intervention type: OTHER
Intervention: 3D CT scan
Description: Measure of bone micro-architecture by 3D micro-tomography
Study: NCT04021771

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Curriculum Intervention
Description: The intervention includes: 1) Online web-based education module created with the Rise 360 platform that has ten lessons, providing the learner with an introduction, background, and a map of how to navigate a discharge conversation for patients with diagnostic uncertainty. Core content are presented with multiple interactive components such as flip-cards, multiple-choice, drag-and-drop, sketch videos, and narrated clips. 2) Mobile application game designed to facilitate practice of the content learned in the online curriculum 3) Deliberate practice sessions allow trainees to practice communication techniques presented within the online module and to receive feedback on their performance. These sessions will be conducted with standardized patients via a video platform, during a scheduled appointment.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Curriculum Intervention
Description: The intervention includes: 1) Online web-based education module created with the Rise 360 platform that has ten lessons, providing the learner with an introduction, background, and a map of how to navigate a discharge conversation for patients with diagnostic uncertainty. Core content are presented with multiple interactive components such as flip-cards, multiple-choice, drag-and-drop, sketch videos, and narrated clips. 2) Mobile application game designed to facilitate practice of the content learned in the online curriculum 3) Deliberate practice sessions allow trainees to practice communication techniques presented within the online module and to receive feedback on their performance. These sessions will be conducted with standardized patients via a video platform, during a scheduled appointment.
Study: NCT01970397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVEDERM® Ultra XC
Description: Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero Balance®
Description: Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
Study: NCT00816855

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel, cisplatin, fluorouracil
Description: neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly
Study: NCT03481387

Intervention type: DEVICE
Group type: OTHER
Intervention: Aortic Valve Replacement with Perceval S sutureless heart valve
Description: Patients will be treated with the PERCEVAL S heart valve (PERCEVAL S valve) which is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
Study: NCT02629328

Intervention type: DEVICE
Group type: OTHER
Intervention: CardioCel
Description: Treatment with CardioCel implant
Study: NCT04504461

Intervention type: OTHER
Intervention: Analysis of feasibility and costs
Description: Analyze the feasibility and costs of performing laparoscopic inguinal hernioplasty in an ambulatory surgery center

Intervention type: OTHER
Intervention: Analysis of feasibility and costs
Description: Analyze the feasibility and costs of performing laparoscopic inguinal hernioplasty in an ambulatory surgery center
Study: NCT03118076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine and 50 μg dexmedetomidine
Description: Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Nerve blocks were administered with 0.3% ropivacaine.
Study: NCT04132648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Oral supplement one time at 2,000 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral supplement one time at 2,000 mg
Study: NCT02894489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: corneal lenses
Description: wear corneal lenses on daily basis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: large diameter lenses
Study: NCT02673723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docozine
Description: dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The same amount of saline is given for 10 seconds after surface anesthesia
Study: NCT01781871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar13
Description: Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar13
Description: Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax
Description: 0.5ml Pneumovax injected intramuscularly at day 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax
Description: 0.5ml Pneumovax injected intramuscularly at day 1.
Study: NCT04491240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXO 1 inhalation
Description: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXO 2 inhalation
Description: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation
Description: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
Study: NCT02234557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: 6-8 students will be enrolled in 8 weeks of Tai Chi instruction, with two 1-hour sessions per week. Students will be requested to practice from recorded materials at home three times a week for 15-30 minutes each session, and parents will be asked to keep a log of at-home practice.~Class sessions will consist of warm up (qi k'ong), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Practice will consist of warm up, followed by practice of selected pieces of the form.~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing pre-, mid- and postintervention).
Study: NCT04088708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Each session will last 20 to 60 minutes depending on the stage of progression (shorter duration in the first few weeks). Sessions will occur on nonconsecutive days of the week. Moderate-intensity, continuous aerobic exercise will be used to target large muscle groups (e.g., legs) with the principal goal of increasing cardiorespiratory fitness. Exercise intensity will be gradually increased. To mitigate stagnation and support continued improvement of cardiorespiratory fitness, high-intensity interval exercise will be added in later weeks of the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The flexibility/toning control condition will be delivered using the same frequency as the aerobic condition (i.e., 3 times per week) and use light resistance bands of least difficulty. The flexibility/toning sessions will last about 40 minutes, be led by trained exercise specialists. Flexibility/toning activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, and ankle/foot. The progression of activities over the 10-week period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands (i.e., Thera-bands) that provide minimal resistance.
Study: NCT02091921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
Study: NCT02103881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 500 mg of intramuscular ketamine for severe pre-hospital agitation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Haloperidol 10 mg intramuscular for severe prehospital agitation.
Study: NCT04041141

Intervention type: DIAGNOSTIC_TEST
Intervention: CT Scan
Description: An additional cone beam CT will be repeated at midcourse of therapy (3rd week) and during the end of therapy (5th week)

Intervention type: DEVICE
Intervention: Experimental Oral Stent Device
Description: Patients undergoing standard of care planning for head and neck tongue cancer will have a radiation plan of the body imaged via CT scan construction with the experimental oral stent device in place
Study: NCT03058848

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU Start
Description: PKU Start is a powdered, phenylalanine-free, infant formula, containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and long chain polyunsaturated fatty acids (LCPs); Arachidonic acid (AA) and Docosahexaenoic acid (DHA). It is suitable for use from birth.~The recommended amount of the product for each participant will be determined and prescribed by a dietitian.